Physician profile
Michael Lewis
NPI 1487189510
$3,980.90
in general payments reported to CMS, 2019-2025
30 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $530 · 2023: $854 · 2024: $1,166 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,450.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $864.08 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $837.06 | 2022-2025 | |
| Lilly USA, LLC | $419.27 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $301.94 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $271.90 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.79 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $143.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $98.55 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.12 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $77.69 | 2024-2025 | Auvelity |
| Tempus Ai, INC | $68.70 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.08 | 2022 | |
| Astellas Pharma US INC | $66.64 | 2022-2025 | Veozah |
| Abbott Laboratories | $65.25 | 2024-2025 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $53.58 | 2022-2023 | Heplisav-B |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $47.97 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Idorsia Pharmaceuticals US INC | $41.98 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $41.44 | 2025 | Fanapt |
| Halozyme INC | $33.56 | 2023 | |
| Amgen INC. | $32.77 | 2023-2024 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $30.09 | 2022 | |
| Dexcom, INC. | $21.12 | 2024 | Dexcom G6 Transmitter |
| Tris Pharma INC | $18.24 | 2022 | |
| Merck Sharp & Dohme LLC | $16.79 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.59 | 2025 | Voquezna |
| Antares Pharma, INC. | $15.40 | 2024 | Xyosted |
| Esperion Therapeutics, INC. | $14.05 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $13.34 | 2023 | Trelegy Ellipta |
| Sanofi Pasteur INC. | $12.89 | 2023 | |
| Mylan Specialty L.P. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.